Clinical trials: Natural Killer Cell Malignancies
Lymphoid Malignancies
The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
This is an open-label, Phase 1/2 study designed to characterize the safety, tolerability, Pharmacokinetics(PK), and preliminary antitumor activity of AVM0703 administered as a single intravenous (IV) infusion to patients with…
- Trial name
- OPAL (NCT04329728)
- Testing
- AVM0703
- Where
- 11 sites in United States
- Volunteers
- 144 people
- Sponsor
- AVM Biotechnology Inc
Sarcoma
Evaluation of Autologous Natural Killer Cell Activity in Primary Cancer Cell Cultures
The objectives of the study is to evaluate the anti-tumor activity of autologous natural killer cells in cultures of cancer cells obtained from patient's own tumor.
- Trial name
- NCT05869994
- Where
- United States
- Sponsor
- Sarcoma Oncology Research Center, LLC
Triple Negative Breast Cancer
QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.
This is a phase 1b/2 study to evaluate the safety and efficacy of metronomic combination therapy in subjects with TNBC who have progressed on or after previous SoC chemotherapy.
- Trial name
- NCT03387085
- Testing
- Aldoxorubicin HCl, N-803, ETBX-011
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- ImmunityBio, Inc.
Lymphoid Neoplasm
Target Gene Sequencing for Advanced Stage, Relapsed or Refractory Natural Killer/T-cell Lymphoma
Although modern radiation techniques combined with chemotherapy has greatly improved the local control and long-term survivals for patients with early-stage NKTCL, relapse and systemic dissemination are common for localized…
- Trial name
- NCT04509804
- Testing
- non-interventional
- Where
- China
- Volunteers
- 26 people
- Sponsor
- Chinese Academy of Medical Sciences
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer
This phase I/II trial studies the side effects and best dose of donor natural killer (NK) cell therapy and to see how well it works when given together with fludarabine phosphate, cyclophosphamide, total-body irradiation, donor…
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Aggressive Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma
- Trial name
- NCT00789776
- Testing
- Allogeneic Bone Marrow Transplantation, Cyclophosphamide, Fludarabine Phosphate
- Where
- 3 sites in United States
- Volunteers
- 41 people
- Sponsor
- Fred Hutchinson Cancer Center
Ewing Sarcoma, Neuroblastoma
Phase 2 STIR Trial: Haploidentical Transplant and Donor Natural Killer Cells for Solid Tumors
The investigators hypothesize that this Phase 2 cellular and adoptive immunotherapy study using human leukocyte antigen (HLA)-haploidentical hematopoietic cell transplantation (HCT) followed by an early, post-transplant infusion…
- Conditions
- Ewing Sarcoma, Neuroblastoma, Rhabdomyosarcoma, Osteosarcoma
- Trial name
- STIR (NCT02100891)
- Testing
- Allogeneic HCT, Donor NK Cell Infusion
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Monica Thakar
Leukemia
Cord Blood Natural Killer (NK) Cells in Leukemia/Lymphoma
The goal of this clinical research study is to find the highest tolerable dose of immune cells called natural killer (NK) cells that can be given with chemotherapy to patients with CLL.
- Trial name
- NCT02280525
- Testing
- Lenalidomide, Rituximab, Fludarabine
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- M.D. Anderson Cancer Center
Lymphoma, Extranodal NK-T-Cell
18F-FDG PET/CT-based Prognostic Model for Predicting Outcome in Patients With Natural Killer/T-cell Lymphoma
The purpose of this study is to evaluate whether 18F-FDG PET/CT-based prognostic model of NK/T-cell lymphoma can predict disease progression
- Trial name
- NCT03051555
- Testing
- 18F-FDG PET/ CT
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Peking University Cancer Hospital & Institute
Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia
Single vs Double Umbilical Cord Blood Transplants in Children With High Risk Leukemia and Myelodysplasia (BMT CTN 0501)
This study is a Phase III, randomized, open-label, multi-center, prospective study of single umbilical cord blood (UCB) transplantation versus double UCB transplantation in pediatric patients with hematologic malignancies.
- Conditions
- Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Myelodysplastic Syndrome
- Trial name
- NCT00412360
- Testing
- Single Umbilical Cord Blood Unit Transplant, Double Umbilical Cord Blood Unit Transplant, Total Body Irradiation
- Where
- 38 sites in United States, Australia and 1 more
- Volunteers
- 224 people
- Sponsor
- Medical College of Wisconsin
Acute Myeloid Leukemia
Clofarabine Plus Cytarabine Versus Conventional Induction Therapy And A Study Of NK Cell Transplantation In Newly Diagnosed Acute Myeloid Leukemia
The purpose of this study is to assess the feasibility and efficacy of a novel form of therapy-haploidentical NK cell transplantation-in patients with standard-risk AML.
- Trial name
- NCT00703820
- Testing
- Cytarabine, Daunorubicin, Etoposide
- Where
- 8 sites in United States, Singapore
- Volunteers
- 324 people
- Sponsor
- St. Jude Children's Research Hospital
Acute Myeloid Leukemia, Myelodysplastic Syndrome
NK Cell Based Non-Myeloablative Transplantation in Acute Myeloid Diseases
This is a phase II multi-institutional therapeutic study of NK-cell based nonmyeloablative haploidentical transplantation for the treatment of high-risk acute myeloid diseases. Enrollment will use a two-stage design.
- Trial name
- NCT01370213
- Testing
- Preparative Regimen, NK Cells, Interleukin-2
- Where
- 4 sites in United States
- Volunteers
- 25 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Advanced Hepatocellular Carcinoma (HCC), Metastatic Liver Cancer
Dual-Target GPC3/B7-H3 CAR-NK Cells for Advanced HCC
open-label trial of an allogeneic dual-target CAR-NK product directed against GPC3 and B7-H3 for adults with advanced hepatocellular carcinoma.
- Trial name
- DUET-HCC (NCT07500220)
- Testing
- EB-G3B7-NK dual-target CAR-NK cells, Fludarabine, Cyclophosphamide
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Beijing Biotech
Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type
Treatment of Relapsed or Refractory Natural Killer/T Cell Lymphoma
The purpose of this study is to evaluate the efficacy and safety of PD-1 blockade pembrolizumab for patients with relapsed or refractory Natural Killer(NK)/T Cell Lymphoma.
- Trial name
- NCT03107962
- Testing
- Pembrolizumab (PD-1 Blocking Antibody)
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Mingzhi Zhang
Non-small Cell Lung Cancer
A Clinical Research of NK Cell Infusion Combined With Chemotherapy in the Treatment of Non-small Cell Lung Cancer
The main purpose of this study is to explore if the combination of autologous NK cell infusion and chemotherapy can increase the therapeutic efficiency in the treatment of non-small cell lung cancer compared with chemotherapy…
- Trial name
- NCT02734524
- Testing
- NK cells, Taxol, Carboplatin
- Where
- China
- Volunteers
- 104 people
- Sponsor
- Southwest Hospital, China
Acute Myeloid Leukemia
Haploidentical NK-cell Infusion in Acute Myeloid Leukemia
Leukemia cells can be killed by natural killer (NK) from HLA-I mismatched donor. The proposed study plans to realize an adoptive anti-leukaemic immunotherapy by infusion of HLA-I mismatched NK cells to treat poor prognosis acute…
- Trial name
- NK (NCT01947322)
- Testing
- Allogenic NK cells infusion
- Where
- 4 sites in France
- Volunteers
- 10 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
AML/MDS, CD33 Expressing Hematological Malignancies
SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS
This is an open-label study of the safety, biodynamics, and anti-cancer activity of SENTI-202 (an off-the-shelf logic gated CAR NK cell therapy) in patients with CD33 and/or FLT3 expressing blood cancers, including AML and MDS.
- Conditions
- AML/MDS, CD33 Expressing Hematological Malignancies, FLT3 Expressing Hematological Malignancies
- Trial name
- NCT06325748
- Testing
- SENTI-202
- Where
- 8 sites in United States, Australia
- Volunteers
- 21 people
- Sponsor
- Senti Biosciences
Epithelial Ovarian Cancer, Fallopian Tube Cancer
Intraperitoneal Delivery of Adaptive Natural Killer (NK) Cells (FATE-NK100) With Intraperitoneal Int
This is a Phase I trial to determine the maximum tolerated dose/maximum feasible dose (MTD/MFD) of a single infusion of FATE-NK100 via intra-peritoneal catheter in women with recurrent ovarian, fallopian tube or primary…
- Conditions
- Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- NCT03213964
- Testing
- FATE-NK100, Interleukin-2
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Relapsed/Refractory Multiple Myeloma
agenT-797 in Participants With Relapsed/Refractory Multiple Myeloma
This is a Phase 1, open-label study to explore the safety, tolerability, and preliminary clinical activity of agenT-797, an unmodified, allogeneic iNKT cell therapy, in participants with relapsed or refractory multiple myeloma…
- Trial name
- NCT04754100
- Testing
- agenT-797
- Where
- 3 sites in United States
- Volunteers
- 13 people
- Sponsor
- MiNK Therapeutics
Acute Lymphoblastic Leukemia, Acute Myelocytic Leukemia
T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant
The primary aim of this protocol is to evaluate if the one-year survival is significantly improved in the group of patients who receive a T-cell replete haploidentical donor hematopoietic cell transplant (HCT) with a novel…
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myelocytic Leukemia, Chronic Myelocytic Leukemia, Juvenile Myelomonocytic Leukemia
- Trial name
- NCT01621477
- Testing
- clofarabine, cytarabine, busulfan
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- St. Jude Children's Research Hospital
Nasal and Nasal-type NK/T-cell Lymphoma
Treatment of Natural Killer/T Cell Lymphoma-Ⅲ/Ⅳ
The purpose of this study is to evaluate the efficacy and safety of DDGP regiment (gemcitabine，pegaspargase,cisplatin,dexamethasone) for patients with stage Ⅲ/Ⅳ Natural Killer (NK)/T Cell Lymphoma.
- Trial name
- CTTNKTL-Ⅲ/Ⅳ (NCT01501149)
- Testing
- DDGP(cisplatin,dexamethasone,gemcitabine,pegaspargase), Modified SMILE （MTX，DEX，IFO，L-ASP，Etoposide，Mesna）
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Mingzhi Zhang